Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188934 | 1.00 | ESR1 (0.43) | ESR1ESR2STSCYP19A1 | |
| SCHEMBL5209471 | 0.88 | ESR1 (0.44) | ESR1ESR2STS | |
| SCHEMBL5201645 | 0.88 | ESR1 (0.44) | ESR1ESR2STS | |
| SCHEMBL5206887 | 0.85 | ESR1 (0.48) | ESR1ESR2 | |
| SCHEMBL5203060 | 0.85 | ESR1 (0.48) | ESR1ESR2 | |
| SCHEMBL5205279 | 0.85 | ESR1 (0.46) | ESR1ESR2 | |
| SCHEMBL5206675 | 0.85 | ESR1 (0.46) | ESR1ESR2STSCYP19A1 | |
| SCHEMBL5208494 | 0.85 | ESR1 (0.46) | ESR1ESR2 | |
| SCHEMBL5209366 | 0.75 | ESR2 (0.73) | ESR1ESR2 | |
| SCHEMBL14205884 | 0.72 | ESR1 (0.47) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809594-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | claimed |
| US-7151196-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-12-19 | — | — | US | claimed |
| WO-2006050402-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060094779-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-05-04 | — | — | US | claimed |
| EP-1809594-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7151196-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-12-19 | — | — | US | disclosed |
| WO-2006050402-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094779-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094779-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885STS 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.